Comparative Pharmacology
Head-to-head clinical analysis: RISPERDAL versus RISVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RISPERDAL versus RISVAN.
RISPERDAL vs RISVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.
Risperidone is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and H1 histaminergic receptors.
2-8 mg orally once daily or divided twice daily; maximum 16 mg/day
70 mg orally once daily, with or without food.
None Documented
None Documented
20 hours (parent drug), 23 hours (active metabolite 9-hydroxyrisperidone). Steady state reached in 5-6 days. Extended in elderly and hepatic/renal impairment.
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 20-30 hours in hepatic impairment (Child-Pugh B/C).
Renal: 70% (30% as unchanged drug, 40% as metabolites), Fecal/Biliary: 14%
Renal: 30% unchanged; Fecal: 65% (biliary excretion of metabolites); 5% other.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic